Click here to go to the previous page
Herbal-induced Liver Injury (HILI): How That May Impact Rx Benefit-Risk
Program Code:
382
Date:
Wednesday, June 26, 2013
Time:
4:00 PM to 5:30 PM
EST
CHAIR
:
Pradip K. Paul,
MD,MS (SCHNON), Senior Director, Head, Aggregate Reports and Risk Management, GPS,
Vertex Pharmaceuticals, United States
Dr. Pradip Paul is a safety physician experienced in global pharmacovigilance & risk management, actively engaged in executive roles with major ethical pharmaceutical companies. At DIA he is the co-chair of Clinical Safety & Pharmacovigilance Track, & chair for the Natural Health Products SIAC.
|
SPEAKER
(S):
Pradip K. Paul,
MD,MS (SCHNON), Senior Director, Head, Aggregate Reports and Risk Management, GPS,
Vertex Pharmaceuticals, United States
Dr. Paul is engaged in the Pharmacovigilance for over 12 years, and 19 years of experience in Clinical research. He received his medical degree from Dhaka Medical Collage and his MS from NJIT, USA. Earlier he worked in Ciba-Geigy, Schering AG, and currently working at Sanofi-aventis.
|
Victor J. Navarro, MD (SPKSUP), Chair, Hepatology, Einstein Medical Center, United States
Dr. Seef joined NIH as Senior Scientist for Hepatitis Research where he helped develop & oversee several NIDDK-funded multicenter studies. When he retired from the NIH he joined FDA as a consultant in Hepatology. He is a member of the AASLD & is the senior author of numerous AASLD guidelines.
|
Description
Natural health products (NHP) safety plays an important role in the possible risk assessment of a compound under development or a product in the market. This important noise can be reduced, and recalibration of internal evaluation processes is needed.
This session has been developed by the Natural Health Products (NHP) Community.